// App-Quantinova.ai

: Impact of COVID-19 on patients with severe alpha1 antitrypsin deficiency: the IMCA1 study of the EARCO ERS Clinical Research Collaboration, preliminary findings

Researchers

Presenter

  • David G. Parr

Principal Investigators

  • Christian Clarenbach

  • Joanna Chorostowska-Wynimko

  • Angelo Corsico

  • Ilaria Ferrarotti

  • Lourdes Lázaro-Asegurado

  • Jose Lopez-Campos

  • Adriana Rozy

  • Annelot Sark

  • Maria Sucena

  • Jan Stolk

  • Eva Tabernero Huguet

  • Hanan Tanash

  • Marc Miravitlles

Medical Centers

  • University Hospital of Zurich, Zurich, Switzerland

  • Leiden University Medical Centre, Leiden, Netherlands

  • Centro Hospitalar e Universitário do Porto, Porto, Portugal

  • University Hospital, Coventry, Coventry, West Midlands, United Kingdom

  • Lund University Hospital, Lund, Sweden

  • Vall d´Hebron Hospital Campus, Barcelona, Spain

  • Hospital Universitario de Cruces, Biocruces-Bizkaia, Spain

  • Burgos University Assistance Complex, Burgos, Spain

  • Institute for Tuberculosis and Lung Disease, Warszawa, Poland

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • University of Pavia, Pavia, Italy

Locations

  • Sweden

  • Portugal

  • United Kingdom

  • Switzerland

  • Poland

  • Italy

  • Netherlands

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Pulmonary/Respiratory Diseases

  • Gastroenterology (GU)

  • Genetic Disorder

Disease

  • Coronavirus disease

  • Alpha-1 antitrypsin (A1AT) deficiency

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved